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MISCELLANEOUS
Purpose: To evaluate the use of desipramine in the treatment of overactive bladder (OAB).
Materials and Methods: We retrospectively evaluated 43 patients who were treated with 
desipramine for OAB refractory to antimuscarinic therapy. These OAB patients were strati-
fied by the presence or absence of bladder pain. 
Results: Forty-three patients were evaluated with a mean follow up time of 12.2 ± 4.6 months. 
The mean age of the patients was 71 ± 16 years. Twelve patients (28%) discontinued desip-
ramine, 9 due to perceived lack of efficacy, 2 due to central anticholinergic side effects, and 
1 due to the development of oropharyngeal sores.  Patients were stratified into two subgroups 
based upon treatment with desipramine for OAB alone (n = 29) or OAB and bladder pain (n 
= 14). There was no difference between the groups in regard to sex (P = .34), prior history of 
radiation (P = .19), side effects (P = .16), and specifically evaluated central anti-cholinergic 
side effects (P = .66). There was no statistical difference in the self-reported success rate of 
the medication (P = .48). In the OAB plus bladder pain subgroup, 71% of patients reported 
improvement in their pain. Overall, 13 (30%) patients had history of prior pelvic radiation 
and 10 of those (77%) reported improvement with desipramine.
Conclusion: Desipramine is a potential useful treatment for patients with OAB. In addition, 
it can be used in patients with OAB and bladder pain and patients with complex OAB such 
as OAB caused by pelvic radiation. 
Keywords: urinary incontinence, urge; cholinergic antagonists; drug therapy; antidepressive 
agents, tricyclic; treatment outcome.
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INTRODUCTION
Overactive bladder (OAB) is a condition character-ized by increased urinary urgency, with or without incontinence.(1) Its prevalence has been estimated 
to range between 11.8% and 14%, slightly lower in men 
than in women.(2,3) This symptom profile has been shown in 
several studies to increase with age.(2,4,5) The incidence in-
creases from 10.5% for patients aged 18-24, up to 21.9% for 
those aged greater than 65 years.(3) In elderly patients who 
fail conservative treatments for OAB, pharmacologic man-
agement can be challenging.(6) Traditionally, anticholinergic 
agents such as oxybutynin are used as a first-line pharma-
cologic treatment.(7) If the patient symptoms are refractory 
to treatment with traditional first-line anticholinergic agents, 
tricyclic antidepressants (TCAs) such as amitriptyline and 
imipramine can be prescribed. However, a limitation of all 
anticholinergic agents on the market is their lack of specific-
ity for muscarinic receptors of the bladder. As a result, cen-
tral anticholinergic side-effects including memory defects, 
fatigue, and impaired balance can often be experienced.(6) 
Furthermore; elderly patients are particularly vulnerable to 
these side-effects associated with the central anticholinergic 
effects of TCAs. This is due in part to an increased anticho-
linergic load, polypharmacy, a natural age-related decline 
in cholinergic function, and declining function of the blood 
brain barrier.(6)
Desipramine is an active metabolite of imipramine. It is dis-
tinguished by the presence of only one n-methyl group on 
its side chain.(7) It has been shown in several studies to have 
less central nervous system (CNS) side effects than other 
TCA agents including imipramine and amitriptyline.(7-9) No 
published study has evaluated the use of desipramine as a 
treatment for OAB. Herein, we report on our experience with 
desipramine for the primary treatment of symptomatic OAB 
with the goal of minimizing CNS-related side-effects. 
MATERIALS AND METHODS
Data Collection
Data was prospectively collected on patients that were pre-
scribed desipramine by a single physician (GHW) for the 
second-line treatment of OAB over a two year period span-
ning between 2010 and 2011. Diagnosis of OAB was based 
upon established AUA guidelines.(10) Patients were informed 
about the off-label use of desipramine for this purpose. An 
inclusion criterion was OAB refractory to prior anticholin-
ergic treatment. Patient demographics, clinical characteris-
tics, and patient-reported outcomes, and side-effect profiles 
while taking desipramine were retrospectively reviewed. Pa-
tients were followed serially at monthly visits to assess the 
therapeutic effects as well as side effects of the medication 
regimen. Data collection and analysis for this study was ap-
proved by the Institutional Review Board (IRB) and all pa-
tient data was stored in a secure patient de-identified database 
in accordance with the IRB approval. 
Statistical Analyses
All statistical analyses were conducted on Microsoft Excel 
2007 platform. Continuous and categorical variables were 
analyzed using Mann-Whitney U test and Chi-Squared test, 
respectively. 
RESULTS
Forty-three patients were evaluated who were prescribed 
desipramine after failing treatment with at least one anti-
muscarinic agent. Failure from an antimuscarinic agent was 
determined through chart review. The initial dosing of all pa-
tients was 10 mg. The range of final dosing was 10 mg to 75 
mg. Two patients (5%) dosages were raised to 25 mg, 3 (7%) 
to 50 mg and 1 (2%) to 75 mg. Their dosages were raised 
based on clinical evaluation of patient self-reported symptom 
benefit and side effects. The mean age of the patients was 71 
± 16 years (Table 1). Twenty-three patients (53%) were male 
and 20 (47%) were female. Overall, 13 (30%) patients had 
history of prior pelvic radiation and 10 of those (77%) re-
ported improvement with desipramine. Thirty-one (72%) of 
the original 43 patients continue to take desipramine as pre-
scribed at a mean follow up of 12.2 ± 4.6 months, reporting 
clinical benefit and improvement of their OAB symptoms. 
Twelve patients (28%) discontinued desipramine, 9 (75%) 
due to perceived lack of efficacy, 2 (17%) due to central an-
ticholinergic side effects, and 1 (8%) due to the development 
of oropharyngeal sores. The average duration of compliant 
use of the medication in these patients who discontinued 
use was calculated at 6 ± 3.4 months. Overall, 12 patients 
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reported side effects from the medication, the most common 
being dry mouth (n = 5, 42%), constipation (n = 2, 17%), and 
fatigue (n = 3, 25%).
Furthermore, patients were stratified into two subgroups 
based upon desipramine treatment for OAB alone (n = 29) or 
OAB combined with bladder pain (n = 14) (Table 2). There 
was no difference noted between the groups in regard to sex 
(P = .34), prior history of pelvic radiation (P = .19), side ef-
fects (P = .16), and specifically assessed central anticholin-
ergic side effects (P = .66). However, the OAB plus bladder 
pain group was significantly older (P = .05). There was no 
statistical difference in the self-reported success rate of the 
medication (P = .48). In the OAB plus bladder pain group 10 
(71%) patients reported improvement in their pain in addi-
tion to OAB symptoms.
DISCUSSION
CNS side effects from treatment with anti-muscarinic agents 
include headache, fatigue, dizziness, cognitive impairment, 
confusion, and insomnia.(11) TCAs have similar side-effects 
due to their adjunct anticholinergic properties.(11-13) More el-
derly patients are more likely to suffer from OAB and are 
also more likely to experience anticholinergic side-effects 
from the medications used to treat their symptoms.(12) This 
increased risk is commonly attributed, at least in part, to 
polypharmacy which is more prevalent in this population 
with more comorbidity. Gardner and colleagues estimated 
that between 21% and 32% of nursing home residents are 
simultaneously prescribed two or more medications with an-
ticholinergic activity.(3,13) In addition, the elderly may have 
diminished efficiency of drug metabolism and elimination, 
leading to an increased anticholinergic “load” effectively.(14) 
Delirium can be caused by blockage of brain muscarinic re-
ceptors and drugs with anticholinergic activity are the most 
common cause of drug-induced delirium.(15,16) 
Among the TCA agents, desipramine has been noted to have 
the least anticholinergic affect.(15) In initial clinical trials, it 
was noted to have less CNS side effects when compared to 
imipramine.(9) These findings were corroborated in two sub-
sequent studies.(7,11) A randomized control trial of 20 patients 
comparing imipramine and desipramine use for the treatment 
of major depression, found that although desipramine was 
not superior to imipramine in its treatment of depression 
symptoms, it is less likely to produce central anticholinergic 
side effects such as headache, tremors, and dizziness.(10) Di 
Mascio and colleagues enrolled 7 blinded subjects who were 
given either a dose of imipramine (50 mg, 100 mg or 200 
mg) desipramine (50 mg, 100 mg, and 200 mg) or a placebo. 
Subjects were then tested performing various cognitive and 
visou- motor tasks such as typing, aiming and performing 
calculations. They found that imipramine produced marked 
impairment in intellectual and visuo-motor function in com-
parison to desipramine.(7) 
Desipramine has also been compared to amitriptyline in head-
to-head investigation. In a double blinded crossover study by 
Blackwell and colleagues, nine healthy female volunteers 
Table 1. Baseline characteristics of patients prescribed desipramine 
for overactive bladder. 
Patients
Number 43
Male 23
Female 20
Age ± SD, years 71 ± 16
Side effects, n (%) 12 (28)
Central anticholinergic side effects, n (%) 7 (16)
Prior pelvic radiation, n (%) 13 (30)
Patients doing well on medication, n (%) 31 (72)
Key: SD, standard deviation.
Table 2. Comparison of patients prescribed desipramine for overactive 
bladder only and for overactive bladder plus bladder pain.
OAB Only OAB and Bladder Pain P
Number 29 14 -
Male 18 5 .19
Female 11 9
Age ± SD, years 68.4 ± 18.0 76.7 ± 8.5 .05
Side effects, n (%) 6 (21%) 6 (43) .16
Central anticholinergic side ef-
fects, n (%) 4 (14) 3 (21) .66
With prior pelvic radiation, n (%) 9 (31.0) 4 (28.6) .34
 Patients doing well on medica-
tion, n (%) 22 (75.8) 9 (64.3) .48
Key: SD, standard deviation; OAB, overactive bladder.
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were given three different doses of desipramine (25 mg, 50 
mg, and 100 mg), three different doses of amitriptyline (25 
mg, 50 mg, and 100 mg) and placebo. The patients then were 
asked to rate their sedation on Clyde Mood Scale. Amitrip-
tyline was noted to produce more sedation at all levels and 
was clinically significant at 50 mg (P < .01).(8) In a study 
of pigeons by Vaillant, the central anticholinergic effects of 
desipramine, amitriptyline and imipramine were assessed 
by measuring their ability to mask the central muscarinic ef-
fects of physostigmine.(17) Desipramine was found to be the 
least effective in CNS function of the TCAs tested, requir-
ing the highest dose to reverse the central muscarinic activity 
of physostigmine. Furthermore, in a study by Abernethy and 
colleagues, metabolic clearance of desipramine was found to 
be less affected by increasing age than that of imipramine.(18) 
In consideration of its decreased central anticholinergic ac-
tivity, we sought to report on the use of desipramine for pa-
tients with OAB refractory to treatment with first-line anti-
muscarinic agents. To our knowledge this is the first study 
reporting on the use of desipramine for OAB. Our results 
indicate that it is well tolerated in a population of patient’s 
refractory to antimuscarinic therapy. Also significant was that 
77% of patients with prior history of pelvic radiation reported 
improved symptoms following desipramine treatment, as this 
population can be difficult to treat.(21) Furthermore, only two 
patients discontinued the medication due to central anticho-
linergic side-effects and the vast majority (72%) reported im-
provement on the prescribed therapy with desipramine.
Patients with bladder pain and OAB can be difficult to man-
age, since many of them can fall into the Interstitial Cystitis/
Bladder Pain Syndrome (IC/BPS) spectrum.(19) For IC/BPS 
patients’ amitriptyline has been the most extensively TCA 
agent studied. In a large double blinded randomized control 
trial by Foster and colleagues comparing behavior modifica-
tion and education with and without amitriptyline, they found 
that patients who could tolerate a low dosing (25 mg) had sig-
nificant benefit from the drug.(20) Desipramine has also been 
studied in the setting of IC/PBS. Renshaw reported on the 
successful use of desipramine in a single patient.(21) In our 
study we reported 71% of patients subjectively reported an 
improvement in their bladder pain.
Our study is limited by its retrospective nature and single-
arm design which cannot fully access the comparative effi-
cacy of desipramine as a single-agent treatment modality for 
OAB. Future, prospective randomized studies are needed on 
this topic to fully elucidate the utility and side-effect profile 
of desipramine over other agents as a treatment option for 
OAB.
CONCLUSION
Our experience to date has demonstrated desipramine as a 
useful potential treatment for patients with OAB refractory to 
first-line antimuscarinic therapy, possibly providing an alter-
native treatment modality with a mechanistically minimized 
risk of CNS side-effects compared to other TCAs.
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